Pfizer Inc. said Monday that a closely watched experimental Alzheimer’s drug failed to slow the disease in one late-stage study, but the drug maker said it will continue to study the drug’s effect on a different group of patients.
Pfizer, which is testing bapineuzumab with partner Johnson & Johnson, said the injected drug didn’t slow mental or functional decline in patients with mild or moderate Alzheimer’s disease. The study included patients who carry a gene called ApoE4, which gives people a higher risk of developing the memory-robbing disorder.
About half the population does not carry that gene, however, and Pfizer says a study of the drug in patients without the gene is continuing. Results of that study are expected to be announced later this summer.
JOIN THE DISCUSSION | Register here
We welcome comments. Please keep them civil, short and to the point. ALL CAPS, spam, obscene, profane, abusive and off topic comments will be deleted. Repeat offenders will be blocked. Thanks for taking part — and abiding by these simple rules. A thorough explanation of rules of conduct can be found in our Terms of Service. If you have any questions, including why your comment may not be showing immediately after you submit it, be sure to visit the commenting FAQ.